ALK and non-small cell lung carcinoma: The identification of aberrantly activated tyrosine kinases in a subset of non–small cell lung cancer (NSCLC) has accelerated the approval of ALK tyrosine kinase inhibitors, which have improved the progression-free survival for patients.